Interventional Pain Medicine Physician - 208VP0014X
Customize your policy alerts
Sign up for Interventional Pain Medicine Physician - 208VP0014X policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Interventional Pain Medicine is the discipline of medicine devoted to the diagnosis and treatment of pain and related disorders principally with the application of interventional techniques in managing subacute, chronic, persistent, and intractable pain, independently or in conjunction with other modalities of treatment.
| Field | Value |
|---|---|
| Code | 208VP0014X |
| Grouping | Allopathic & Osteopathic Physicians |
| Classification | Pain Medicine |
| Specialization | Interventional Pain Medicine |
| Category | Individual |
NPI Registrations
8.6K NPIs are registered under this taxonomy code nationwide.
The table below splits that total by NPI type — Type 1 covers individual practitioners, Type 2 covers organizations and facilities — followed by the five states with the most NPIs registered under this taxonomy code.
Medicare: Top Billing Codes by Claims
Medicare claims nationally billed by providers whose primary NUCC taxonomy is this code, broken down by billing code. This is a narrower population than the NPI Registrations count above, which includes providers holding this code as a secondary specialty — the two sections are not directly comparable. Source: CMS Medicare Physician & Other Practitioner by Provider and Service data.
650 rows
| Code | Description | Avg Paid | Claims |
|---|---|---|---|
| J1100 | J1100 – Injection, dexamethasone sodium phosphate, 1 mg | $0 | 911.4K |
| 99214 | 99214 – The provider sees an established patient for an office visit or other outpatient visit invol… | $91 | 753.8K |
| J3301 | J3301 – Injection, triamcinolone acetonide, not otherwise specified, 10 mg | $1 | 581.1K |
| 99213 | 99213 – The provider sees an established patient for an office visit or other outpatient visit invol… | $64 | 449K |
| Q9966 | Q9966 – Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | $0 | 378K |
| J0585 | J0585 – Injection, onabotulinumtoxina, 1 unit | $5 | 349.2K |
| K1034 | K1034 – Provision of covid-19 test, nonprescription self-administered and self-collected use, fda ap… | $12 | 209.2K |
| 80307 | 80307 – The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to sc… | $60 | 178.7K |
| J3300 | J3300 – Injection, triamcinolone acetonide, preservative free, 1 mg | $3 | 178K |
| Q9967 | Q9967 – Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | $0 | 136.5K |
Showing 1–10 of 650
Medicare: Top Providers by Revenue
The highest-revenue Medicare providers whose primary NUCC taxonomy is this code. This list can overlap with the Medicaid list below — a provider can rank highly in both programs.
Medicaid: Revenue by Year
Medicaid: Top Billing Codes by Claims
Medicaid claims billed by providers whose primary NUCC taxonomy is this code, broken down by state. This is a narrower population than the NPI Registrations count above, which includes providers holding this code as a secondary specialty — the two sections are not directly comparable. Source: state Medicaid claims data.
734 rows
| Code | Description | Avg Paid | Claims |
|---|---|---|---|
| 99214 | 99214 – The provider sees an established patient for an office visit or other outpatient visit invol… | $46 | 4.5M |
| 99213 | 99213 – The provider sees an established patient for an office visit or other outpatient visit invol… | $29 | 3M |
| 80307 | 80307 – The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to sc… | $31 | 1.1M |
| 80305 | 80305 – The lab analyst performs presumptive drug test(s) by any method that the analyst can read by… | $6 | 562.2K |
| G0480 | G0480 – Drug test(s), definitive, utilizing (1) drug identification methods able to identify individ… | $49 | 300.5K |
| G8427 | G8427 – Eligible clinician attests to documenting in the medical record they obtained, updated, or r… | $0 | 262.5K |
| 96127 | 96127 – The provider performs a brief emotional/behavioral assessment of the patient using a standar… | $4 | 204.9K |
| J1100 | J1100 – Injection, dexamethasone sodium phosphate, 1 mg | $1 | 201.9K |
| 99204 | 99204 – The provider sees a new patient for an office visit or other outpatient visit involving eval… | $81 | 197.9K |
| 99309 | 99309 – The provider sees a patient for a subsequent nursing facility care visit involving evaluatio… | $12 | 178.1K |
Showing 1–10 of 734
Medicaid: Top Providers by Revenue
The highest-revenue Medicaid providers whose primary NUCC taxonomy is this code. This list can overlap with the Medicare list above — a provider can rank highly in both programs.
| Provider | State | Revenue |
|---|---|---|
| COMMONWEALTH PAIN ASSOCIATES, PLLC | KY | $42.2M |
| ADVANCED PAIN MANAGEMENT SPECIALISTS, LLC | MD | $33.8M |
| PAIN CENTER OF ARIZONA PC | AZ | $21.3M |
| CENTER FOR PAIN MANAGEMENT, LLC | MD | $18.8M |
| AHURA HEALTHCARE CORPORATION | CA | $17.9M |
| CENTER FOR INTERVENTIONAL PAIN SPINE LLC | DE | $17.5M |
| ARIZONA SPINE AND PAIN SPECIALISTS LLC | AZ | $14.1M |
| INTEGRATED PAIN SOLUTIONS PLLC | NC |
Frequently Asked Questions
References
- 1.NPI Registry. Centers for Medicare & Medicaid Services (CMS), National Plan and Provider Enumeration System (NPPES). Retrieved Aug 11, 2026.The public NPPES lookup tool for verifying a provider's National Provider Identifier, practice address, and taxonomy classification.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.